tetano
Editor, Senior Moderator
AMB Express
. 2022 Feb 12;12(1):18.
doi: 10.1186/s13568-022-01355-4.
Specific anti-SARS-CoV-2 S1 IgY-scFv is a promising tool for recognition of the virus
Shikun Ge[SUP] 1 2 [/SUP], Rao Wu[SUP] 1 [/SUP], Tingting Zhou[SUP] 3 [/SUP], Xiang Liu[SUP] 1 [/SUP], Jin Zhu[SUP] 3 [/SUP], Xiaoying Zhang[SUP] 4 5 6 [/SUP]
Affiliations
Abstract
As severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to spread globally, a series of vaccines, antibodies and drugs have been developed to combat coronavirus disease 2019 (COVID-19). High specific antibodies are powerful tool for the development of immunoassay and providing passive immunotherapy against SARS-CoV-2 and expected with large scale production. SARS-CoV-2 S1 protein was expressed in E. coli BL21 and purified by immobilized metal affinity chromatography, as antigen used to immunize hens, the specific IgY antibodies were extracted form egg yolk by PEG-6000 precipitation, and the titer of anti-S1 IgY antibody reached 1:10,000. IgY single chain variable fragment antibody (IgY-scFv) was generated by using phage display technology and the IgY-scFv showed high binding sensitivity and capacity to S1 protein of SARS-CoV-2, and the minimum detectable antigen S1 protein concentration was 6 ng/µL. The docking study showed that the multiple epitopes on the IgY-scFv interacted with multiple residues on SARS-CoV-2 S1 RBD to form hydrogen bonds. This preliminary study suggests that IgY and IgY-scFv are suitable candidates for the development of immunoassay and passive immunotherapy for COVID-19 to humans and animals.
Keywords: Chicken IgY single chain variable antibody fragment (IgY-scFv); Coronavirus disease 2019 (COVID-19); Egg yolk antibody (IgY); IgY technology; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Spike (S) protein S1 subunit.
. 2022 Feb 12;12(1):18.
doi: 10.1186/s13568-022-01355-4.
Specific anti-SARS-CoV-2 S1 IgY-scFv is a promising tool for recognition of the virus
Shikun Ge[SUP] 1 2 [/SUP], Rao Wu[SUP] 1 [/SUP], Tingting Zhou[SUP] 3 [/SUP], Xiang Liu[SUP] 1 [/SUP], Jin Zhu[SUP] 3 [/SUP], Xiaoying Zhang[SUP] 4 5 6 [/SUP]
Affiliations
- PMID: 35150368
- DOI: 10.1186/s13568-022-01355-4
Abstract
As severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to spread globally, a series of vaccines, antibodies and drugs have been developed to combat coronavirus disease 2019 (COVID-19). High specific antibodies are powerful tool for the development of immunoassay and providing passive immunotherapy against SARS-CoV-2 and expected with large scale production. SARS-CoV-2 S1 protein was expressed in E. coli BL21 and purified by immobilized metal affinity chromatography, as antigen used to immunize hens, the specific IgY antibodies were extracted form egg yolk by PEG-6000 precipitation, and the titer of anti-S1 IgY antibody reached 1:10,000. IgY single chain variable fragment antibody (IgY-scFv) was generated by using phage display technology and the IgY-scFv showed high binding sensitivity and capacity to S1 protein of SARS-CoV-2, and the minimum detectable antigen S1 protein concentration was 6 ng/µL. The docking study showed that the multiple epitopes on the IgY-scFv interacted with multiple residues on SARS-CoV-2 S1 RBD to form hydrogen bonds. This preliminary study suggests that IgY and IgY-scFv are suitable candidates for the development of immunoassay and passive immunotherapy for COVID-19 to humans and animals.
Keywords: Chicken IgY single chain variable antibody fragment (IgY-scFv); Coronavirus disease 2019 (COVID-19); Egg yolk antibody (IgY); IgY technology; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Spike (S) protein S1 subunit.